Why the study?
Hyperandrogenism during menopause is often underestimated and attributed to natural aging, yet it can be associated with metabolic abnormalities linked by insulin resistance.
Surgical treatment of post-menopausal ovarian hyperandrogenism can resolve hirsutism and improve glucometabolic profiles in affected patients.
May prompt evaluation of hyperandrogenism in obese postmenopausal T2D patients; leaves open prospective studies on its metabolic associations.
Hyperandrogenism during menopause is often underestimated by clinicians and attributed to the natural aging process. Hyperandrogenism can be associated with some metabolic abnormalities linked together in a vicious circle by insulin resistance. We present the case of an elderly woman affected with type 2 diabetes and obesity who reported the occurrence of clinical hirsutism after physiological menopause at the age of 47 years. At presentation, physical examination and Ferriman-Gallwey score revealed a condition of moderate hirsutism, with markedly increased levels of plasma testosterone and delta-4-androstenedione, obesity (body mass index 31.9), and inadequate glycemic control (glycated hemoglobin 65 mmol/mol). The patient underwent a thorough differential diagnosis by a multidisciplinary team approach, including the various causes of hyperandrogenism during menopause. After choosing surgical option as the appropriate treatment, clinical resolution of hirsutism was observed alongside patient satisfaction and marked improvement of the glucometabolic profile.
No takes yet. Share an insight, caveat, or question.
Taddeo et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: